# ABN Asia Ventures into Bioinformatics, and the inspiring story of the promise: From 92 years old Back to 25

ABN Asia is officially venturing into bioinformatics, entering one of the most exciting frontiers at the intersection of biology, artificial intelligence and computing.

The ambition is bold: to contribute to technologies that could one day help us understand—and potentially reverse—some aspects of biological ageing.

Science fiction has imagined this for decades.

In the 2011 film In Time, starring Justin Timberlake, humans stop ageing when they reach 25. Someone can be 100 years old chronologically while remaining biologically 25.

Today, science cannot do that.

But something extraordinary has already happened in real biology.

The discovery that changed the question

In 2006, Japanese scientist Shinya Yamanaka and his colleagues demonstrated that mature cells could be reprogrammed back into a pluripotent, stem-cell-like state.

The breakthrough involved four transcription factors known as the Yamanaka factors, or OSKM:

Oct4 · Sox2 · Klf4 · c-Myc

Yamanaka's discovery fundamentally changed our understanding of cellular identity and earned him the 2012 Nobel Prize in Physiology or Medicine.

The implication was profound:

A mature cell is not necessarily permanently locked into its biological age and identity.

At least under laboratory conditions, its state can be reprogrammed.

Think of a cell as a legal system

The easiest way to understand this is through an analogy.

A cell is like a highly sophisticated organisation operating under a vast legal framework:

DNA = the entire system of laws
Genes = individual laws
mRNA = instructions derived from those laws
Proteins = the machinery and institutions that execute them

Ageing does not necessarily mean that the original "laws" have disappeared.

The problem may be that the system executing them has changed.

That raises a remarkable possibility:

What if some aspects of biological ageing can be reset by changing how the existing genetic information is interpreted?

The problem with c-Myc

There is an important catch.

The M in OSKM—c-Myc—is also closely associated with cancer biology. That makes unrestricted cellular reprogramming unsuitable as a simple anti-ageing treatment.

Researchers therefore began investigating whether some rejuvenating effects could be achieved without c-Myc.

This led to approaches using OSK: Oct4, Sox2 and Klf4.

Research into partial reprogramming has produced intriguing results in animal and cellular models, suggesting that some age-associated biological characteristics may be reversible.

But we must be precise:

Nobody can currently take a 92-year-old human and safely turn that person into a biologically 25-year-old human.

That remains a scientific challenge.

And that is exactly why ABN Asia is entering the field.

Why bioinformatics?

The next breakthroughs in biotechnology will increasingly depend on the ability to process enormous quantities of biological information.

Genomes.

Transcriptomes.

Proteomes.

Epigenetic data.

Single-cell measurements.

Protein interactions.

Disease pathways.

Ageing biomarkers.

And increasingly, data generated from experiments involving cellular reprogramming.

This is where bioinformatics becomes critical.

ABN Asia sees an emerging convergence:

Biology + Data + AI + Computing = Bioinformatics

AI can help researchers search enormous biological datasets, identify patterns, model interactions and generate hypotheses that can subsequently be tested experimentally.

The laboratory produces the data.

Bioinformatics organises and interprets it.

AI helps discover patterns.

Computing turns those discoveries into scalable systems.

We are not betting on immortality

ABN Asia's interest is not based on the promise that humans will soon live forever.

The more immediate opportunity is much more practical.

What if we could understand why particular cells age?

What if we could identify which biological processes are reversible?

What if different tissues could be rejuvenated independently?

What if ageing-related damage could be addressed before it becomes disease?

The applications could eventually extend across regenerative medicine, ophthalmology, wound healing, neurological research, dermatology and many other areas.

The economic opportunity is enormous.

But more importantly, the scientific opportunity is even larger.

ABN Asia's next frontier

ABN Asia was built around the idea that technology and academia can meet opportunity.

Our venture into bioinformatics extends that mission into one of the deepest technological challenges of the 21st century.

We are entering a field where the fundamental infrastructure of life itself becomes data.

Our objective is to build capabilities at the intersection of:

AI × Bioinformatics × Genomics × Computational Biology

We believe the next generation of biotechnology companies will not be purely biological.

They will be computational.

They will be data-driven.

And increasingly, they will be AI-native.

The world is not yet living in In Time.

A 92-year-old cannot simply become 25.

But science has already shown us something remarkable:

The biological state of a cell is more programmable than we once believed.

ABN Asia is now entering the field to explore what comes next.

Author

Ai Base Network (ABN), ABN ASIA was founded by people with deep roots in academia, with work experience in the US, Holland, Hungary, Japan, South Korea, Singapore, and Vietnam. ABN Asia is where academia and technology meet opportunity. With our cutting-edge solutions and competent software development services, we're helping businesses level up and take on the global scene. Our commitment: Faster. Better. More reliable. In most cases: Cheaper as well.

Feel free to reach out to us whenever you require IT services, digital consulting, off-the-shelf software solutions, or if you'd like to send us requests for proposals (RFPs). You can contact us at [email protected]. We're ready to assist you with all your technology needs.